Related Experiment Video
Updated: Nov 22, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
A SARS-CoV-2 antiviral therapy score card
1Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA.
Researchers prioritized COVID-19 treatments, focusing on repurposed drugs like RNA polymerase inhibitors and entry inhibitors. Ideal therapies are inexpensive and suitable for non-hospitalized patients with SARS-CoV-2 infection.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- Over 750 clinical trials are investigating SARS-CoV-2 treatments, primarily repurposed drugs.
- Novel antiviral drugs require significant development time before human testing.
Discussion:
- Prioritized treatments include viral RNA polymerase inhibitors (e.g., remdesivir), entry inhibitors (monoclonal antibodies, ACE2 decoys), interferons (β and λ), and inhibitors of TMPRSS2, endosomal trafficking, and pyrimidine synthesis.
- The ideal COVID-19 therapies should be affordable and administrable to non-hospitalized individuals upon diagnosis.
Key Insights:
- Repurposed drugs offer a faster route to potential COVID-19 treatments.
- A multi-pronged approach targeting viral replication and host factors is crucial.
Outlook:
- Further clinical evaluation of prioritized compounds is essential.
- Development of accessible and easily administered treatments is key for pandemic management.
More Related Videos
06:08Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
10:25Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
Related Concept Videos
Subviral Agents
Therapeutic Drug Monitoring: Overview and Classification
Drug Therapy
Antianxiety Medications
Antimicrobial Effectiveness
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Index